The FDA has approved pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma patients with PD-L1 expression, based on the KEYNOTE-689 Phase 3 trial demonstrating improved event-free survival and tumor shrinkage. Separately, UroGen Pharma secured FDA approval for its bladder cancer drug Zusduri despite a mixed advisory committee vote, providing a nonsurgical treatment alternative for recurrent low-grade tumors. Moderna received FDA clearance to expand its RSV vaccine use to more adult patients, marking a significant regulatory win amid recent leadership changes.